Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
NeuroSense Therapeutics Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
NRSN
Nasdaq
2834
www.neurosense-tx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for NeuroSense Therapeutics Ltd.
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
- Jan 6th, 2025 2:00 pm
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
- Dec 23rd, 2024 2:00 pm
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
- Dec 18th, 2024 3:25 pm
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
- Dec 11th, 2024 2:25 pm
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS
- Dec 4th, 2024 1:30 pm
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
- Dec 2nd, 2024 1:30 pm
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
- Nov 21st, 2024 2:20 pm
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
- Oct 28th, 2024 12:30 pm
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
- Oct 28th, 2024 12:00 pm
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
- Oct 24th, 2024 12:30 pm
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
- Oct 15th, 2024 1:15 pm
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
- Oct 9th, 2024 1:00 pm
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
- Oct 7th, 2024 1:00 pm
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
- Sep 24th, 2024 1:05 pm
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
- Sep 24th, 2024 1:00 pm
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
- Aug 30th, 2024 8:30 pm
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug
- Aug 28th, 2024 11:00 am
NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price
- Aug 7th, 2024 6:00 pm
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial
- Aug 1st, 2024 1:15 pm
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
- Jul 9th, 2024 1:27 pm
Scroll